company background image
38 logo

NovoCure DB:038 Stock Report

Last Price

€15.65

Market Cap

€1.6b

7D

11.4%

1Y

-75.5%

Updated

10 Mar, 2024

Data

Company Financials +

38 Stock Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

38 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NovoCure Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NovoCure
Historical stock prices
Current Share PriceUS$15.65
52 Week HighUS$78.30
52 Week LowUS$10.08
Beta0.41
1 Month Change14.83%
3 Month Change36.10%
1 Year Change-75.47%
3 Year Change-86.20%
5 Year Change-65.50%
Change since IPO-9.02%

Recent News & Updates

Recent updates

Shareholder Returns

38DE Medical EquipmentDE Market
7D11.4%2.5%0.3%
1Y-75.5%11.1%4.7%

Return vs Industry: 038 underperformed the German Medical Equipment industry which returned 8.1% over the past year.

Return vs Market: 038 underperformed the German Market which returned 2.1% over the past year.

Price Volatility

Is 38's price volatile compared to industry and market?
38 volatility
38 Average Weekly Movement12.0%
Medical Equipment Industry Average Movement4.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 038's share price has been volatile over the past 3 months.

Volatility Over Time: 038's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20001,453Asaf Danzigerhttps://www.novocure.com

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited Fundamentals Summary

How do NovoCure's earnings and revenue compare to its market cap?
38 fundamental statistics
Market cap€1.62b
Earnings (TTM)-€189.32m
Revenue (TTM)€465.74m

3.5x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
38 income statement (TTM)
RevenueUS$509.34m
Cost of RevenueUS$127.54m
Gross ProfitUS$381.80m
Other ExpensesUS$588.85m
Earnings-US$207.04m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.93
Gross Margin74.96%
Net Profit Margin-40.65%
Debt/Equity Ratio156.9%

How did 38 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.